Activity Overview
The management of hormone receptor-positive, HER2-negative (HR+/HER2–) metastatic breast cancer has undergone rapid evolution in recent years with the development of novel endocrine and targeted therapies designed to address critical unmet needs in selected patients. Navigating the treatment landscape now depends on appropriate molecular testing, as well as patient- and disease-related features, to make effective management decisions.
This live, hybrid symposium brings together expert faculty in the management of HR+/HER2– metastatic breast cancer to discuss best practices for selecting treatment for patients, covering topics ranging from timing and type of molecular testing to treatment based on biomarker status. The content is presented in the Show Me the Data format, which is designed to focus on specific decision points as well as the findings that justify management decisions.
This educational activity is an archive of the live virtual symposium held at the 43rd Annual Miami Breast Cancer Conference® on March 6, 2026.
Target Audience
This educational activity is directed toward medical oncologists, surgical oncologists, oncology nurses, advanced practice professionals, pathologists, and other health care practitioners who manage patients with breast cancer.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Implement best practices for molecular testing in HR+/HER2– metastatic breast cancer, including selection of tissue vs liquid biopsy and indications for repeat testing at progression
- Apply clinical trial and real-world evidence to select and sequence oral selective estrogen receptor degraders (SERDs) after progression on a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor plus endocrine therapy
- Develop treatment strategies for dual resistance, integrating evidence for targeting the PI3K/AKT pathway in patients with co-occurring ESR1 and PIK3CA pathway alterations
Reshma L. Mahtani, DO
Medical Oncologist
Chief of Breast Medical Oncology
Baptist Health Miami Cancer Institute
Miami, FL
Disclosures: Consultant: Agendia, Arvinas, AstraZeneca, Daiichi Sankyo, Eisai, Genentech, Hologic, Lilly, Novartis, Pfizer, Sermonix, Stemline; Grant/Research Support: Gilead Sciences
Kamel Abou Hussein, MD
Assistant Professor of Medicine
Cooper Medical School of Rowan University
Co-Director, Janet Knowles Breast Cancer Center
Cooper University Health Care
Camden, NJ
Disclosures: Advisor, Consultant, Fee-for-Service Recipient: AstraZeneca; Speakers Bureau: Lilly
Irene Kang, MD
Medical Director, Women’s Health Breast Oncology
Assistant Professor, Division of Medical Oncology and Therapeutics
Research
City of Hope Orange County
Irvine, CA
Disclosures: Advisor, Consultant, Fee-for-Service Recipient: AstraZeneca, BioNTech, Caris Life Sciences, Daiichi Sankyo, Gilead, Novartis, Pfizer, Stemline Therapeutics
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here